Summary

Toxoid Vaccine market size was valued at USD million in 2021 and is estimated to reach USD million by 2029, growing at a CAGR of 4.9% during the forecast period (2023-2030). Toxoid vaccines are made from a toxin (poison) that has been made harmless, but that elicits an immune response against the toxin and is used as the antigen in the vaccine to elicit immunity. These vaccines are used to protect against Diphtheria, Tetanus, and pertussis. They create immunity to the parts of the germ that cause disease instead of the germ itself.As per DataM Intelligence, Toxoid Vaccine Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Toxoid Vaccine Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Toxoid Vaccine Market in the United States and Canada produces the utmost share. Whereas the European Toxoid Vaccine Market is projected to continue its presence globally during the period of 2023- 2030.Market DynamicsThe global toxoid vaccines market growth is driven by several factors, such as rising cases of tetanus and diphtheria, increasing government initiatives for vaccination programs, and growing research & development activities for new vaccines.The increasing burden of tetanus infection and different countries’ vaccination campaigns drive global market growth.Rising cases of tetanus and diphtheria are one of the major factors driving the market's growth, especially in developing economies. According to the WHO, there were 11,897 cases of tetanus in 2020. Tetanus is among non-communicable disease contracted through exposure to the spores of the bacterium, Clostridium tetani. All ages people can get infected with tetanus; however, the disease is particularly prominent and severe in neonates and their mothers when the mothers` are unprotected from tetanus by the vaccine, tetanus toxoid. Tetanus toxoid vaccine is used for prevention by developing immunity against the pathogen causing tetanus. The low cost of the tetanus vaccine is also boosting the market's growth. Furthermore, the different initiative campaigns by different organizations worldwide fuel market growth. For instance, Supplementary immunization campaigns/activities (SIAs) and Periodic Intensification of Routine Immunization (PIRI) by WHO, also, 15 July 2022 – The Government of Indonesia, with support from UNICEF and partners, is continuing to drive catch-up efforts across the country to address a significant backslide in childhood immunization caused by COVID-19.The associated side effects will restrain the global Toxoid Vaccine growth.However, the toxoid vaccine market is hampered by several side effects associated with the toxoid vaccine, which lowers its preferability. The vaccine causes redness and pain at the site of injection, fever, fatigue and muscle pains. Also, the bipolar and contractual nature of the toxoid vaccine market leads to a fall in profitability of vaccine manufacturing and low demands for these vaccines in the developed regions.Industry analysis.The global toxoid vaccine report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, epidemiological, pricing analysis, Etc.COVID-19 Impact AnalysisDuring the outburst, the pandemic negatively impacted the global market because to prevent further COVID-19 infection spread, restrictions and regulations were imposed, making it difficult for people to perform immunizations which left a large pool of children unimmunized. For instance, according to the WHO, the third dose of diphtheria, tetanus toxoid, and pertussis-containing vaccine coverage in one-year-olds globally decreased from 86% in 2019 to 81% in 2021, which accounted for around 25 million children missing out on vaccination, 6 million more than in 2019 and the highest number since 2009.Segment AnalysisThe tetanus segment is expected to have a greater grasp of the toxoid vaccine market during the forecast period (2023-2030).The tetanus segment held the largest market share in 2021 and is expected to continue throughout the forecast period (2023-2030), owing to the increasing number of tetanus cases globally. Tetanus is an uncommon but very dangerous disease; of every 10 people who get it, as many as 2 will die and requires treatment in a medical facility, often in a referral hospital. Neonatal tetanus is the most deadly in rural areas, where deliveries occur at home without adequate sterile procedures and in an unclean environment. According to the WHO, it is estimated that neonatal tetanus was reported in about 2,300 newborn children in 2020 and around 4,140 in 2021; the increase is owing to the COVID-19 pandemic. Moreover, according to the WHO, total tetanus reported incidences in 2021 are estimated to be 9,707.Furthermore, The WHO recommends combining vaccines containing diphtheria toxoids, such as Td. Neonatal tetanus can be prevented by immunizing women of reproductive age with TTCV, either during pregnancy or outside of pregnancy; this protects the mother and - through a transfer of tetanus antibodies to the fetus - also her baby. Two DTaP vaccines are available in the United States for the first five doses in children <7 years of age: Daptacel and Infanrix.Geographical AnalysisThe Middle East and Africa are dominating the global Toxoid Vaccine market. The middle east and Africa are assumed to command the global toxoid vaccine market during the forecast period (2023-2030) since there is an increased prevalence of tetanus incidents; for instance, as per the WHO, in 2020, there were around 1,218 cases reported for neonatal tetanus and 7,737 total tetanus incidents reported in Africa which is high compared to other WHO regions. Furthermore, the low immunization efficacy of these regions will contribute to their dominance in upcoming forecast years; for instance, as per the WHO regional office for Africa, the African Region still linger behind other WHO regions of the world for access to immunization; around 1 out of 5 African children fail to receive all the necessary and basic immunizations; therefore, over 30 million African children below the age of five still suffer with vaccine-preventable diseases (VPDs) annually in Africa, over half a million children die annually because of vaccine-preventable diseases, representing approximately 58% of global vaccine-preventable diseases related deaths. Moreover, the African region has the countries with the highest birth rate; for instance, Angola has a birth rate of 43.7, Niger has a birth rate of 43.6, and Mali has a birth rate of 43.2, making them the world's top three countries with highest birth rate, creating opportunity for the growth of toxoid vaccine market in this region.Competitive LandscapeThe global toxoid vaccines market is highly competitive with smaller and major players. Some of the major players in the market include Sanofi, AstraZeneca Plc, Panacea Biotec, Pfizer, GlaxoSmithKline, Merck & Co. Inc., Astellas Pharma Inc., Valeant Pharmaceuticals, Emergent Biosolutions, Bharat Biotech, among others. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the toxoid vaccines market globally. For instance, Also, in April 2021, Pfizer acquired Amplyx Pharmaceutical. Also, in December 2021, Sanofi acquired Amunix immuno-oncology.SanofiOverview: Sanofi was founded in 1973 in Paris, France. Sanofi is a multinational pharmaceutical company engaged in the research, development and manufacturing of pharmaceutical drugs in the prescription market and over-the-counter drugs. Sanofi has Sanofi Pasteur, Genzyme, Shantha Biotechnics, Chattem, Ablynx, and Bioverativ as its subsidiaries.Product Portfolio:The product portfolio of Sanofi for Toxoid Vaccine has Adacel, Hexaxim, Pentaxim, Shan5, ShanTT and Tetraxim.The global toxoid vaccine report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

ページTOPに戻る

Table of Contents